Comparative Pharmacology
Head-to-head clinical analysis: FOLICET versus THIAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLICET versus THIAMINE HYDROCHLORIDE.
FOLICET vs THIAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is reduced to tetrahydrofolate (THF) through the enzyme dihydrofolate reductase. THF is a cofactor in one-carbon transfer reactions involved in purine and pyrimidine synthesis, and amino acid metabolism, essential for DNA synthesis and cell division.
Thiamine hydrochloride is a water-soluble vitamin that acts as a cofactor for several enzymes involved in carbohydrate metabolism, including transketolase, pyruvate dehydrogenase, and α-ketoglutarate dehydrogenase. It is essential for the decarboxylation of α-keto acids and pentose phosphate pathway activity.
1 mg orally once daily. For treatment of megaloblastic anemia, up to 5 mg daily initially.
50-100 mg intravenously or intramuscularly once daily for deficiency; 100 mg intravenously for Wernicke encephalopathy (with 50-100 mg maintenance).
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; may be prolonged up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 9-18 days for whole body stores; plasma half-life: 1.5-2 hours for free thiamine.
Primarily renal elimination: approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal excretion accounts for <15%.
Renal: 40-50% as unchanged drug; metabolites: thiamine pyrophosphate, thiamine monophosphate. Fecal: minimal (<5%).
Category C
Category C
Vitamin
Vitamin